Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows

Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows
Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic hormone-sensitive prostate cancer in comparison with standard of care, according to early findings of a large Phase 3 trial. The study, “Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial,” was presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. At the same time, the findings, “Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer,” were also published in the New England Journal of Medicine.  Xtandi, marketed by Pfizer and Astellas Pharma, is an oral androgen receptor approved to treat prostate cancer that no longer responds to medical or surgical treatment intended to lower testosterone. To address whether Xtandi also works in prostate cancers that are responding to testosterone-lowering treatments, researchers designed the multi-center, global and investigator-initiated ENZAME
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *